Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan (Sac-TMT) in post-chemotherapy metastatic castration-resistant prostate cancer
ChiCTR2600127530Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Radiographic progression-free survival (rPFS). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2600127530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127530.